Tysabri and T-cell lymphoma - a phase IV clinical study of FDA data

Summary:

T-cell lymphoma is reported as a side effect among people who take Tysabri (natalizumab), especially for people who are female, 30-39 old, have been taking the drug for 1 - 6 months also take Ativan, and have Nausea.

The phase IV clinical study analyzes which people have T-cell lymphoma when taking Tysabri. It is created by eHealthMe based on reports of 220,870 people who have side effects when taking Tysabri from the FDA, and is updated regularly.

What is Tysabri?

Tysabri has active ingredients of natalizumab. It is often used in multiple sclerosis. eHealthMe is studying from 221,369 Tysabri users. Check the latest studies of Tysabri.

What is T-cell lymphoma?

T-cell lymphoma (a blood cell cancer) is found to be associated with 127 drugs and 458 conditions by eHealthMe. Check the latest studies of T-cell lymphoma.



On Jun, 13, 2026

220,870 people reported to have side effects when taking Tysabri.
Among them, 17 people (0.01%) have T-cell lymphoma.

Could Tysabri cause T-cell lymphoma?

Among these 17 people:

How long have people been on Tysabri when they have T-cell lymphoma? *

  • < 1 month: 0.0 %
  • 1 - 6 months: 57.14 %
  • 6 - 12 months: 0.0 %
  • 1 - 2 years: 0.0 %
  • 2 - 5 years: 42.86 %
  • 5 - 10 years: 0.0 %
  • 10+ years: 0.0 %

What is the gender of people who have T-cell lymphoma when taking Tysabri? *

  • female: 76.47 %
  • male: 23.53 %

What is the age of people who have T-cell lymphoma when taking Tysabri? *

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 0.0 %
  • 20-29: 0.0 %
  • 30-39: 50.0 %
  • 40-49: 12.5 %
  • 50-59: 31.25 %
  • 60+: 6.25 %

What are other drugs people take besides Tysabri? *

  1. Ativan: 9 people, 52.94%
  2. Prednisolone: 3 people, 17.65%
  3. Vitamin D3: 1 person, 5.88%
  4. Tecfidera: 1 person, 5.88%
  5. Singulair: 1 person, 5.88%
  6. Remicade: 1 person, 5.88%
  7. Pulmicort: 1 person, 5.88%
  8. Pradaxa: 1 person, 5.88%
  9. Nasonex: 1 person, 5.88%
  10. Multaq: 1 person, 5.88%

What are other side effects people have besides T-cell lymphoma? *

  1. Thrombocytopenia (decrease of platelets in blood): 3 people, 17.65%
  2. Primary Myelofibrosis (primary disorder of the bone marrow): 3 people, 17.65%
  3. Myelodysplastic Syndrome (a group of conditions that occur when the blood-forming cells in the bone marrow are damaged): 3 people, 17.65%
  4. Rashes (redness): 2 people, 11.76%
  5. Muscle Spasms (muscle contraction): 2 people, 11.76%
  6. Fatigue (feeling of tiredness): 2 people, 11.76%
  7. Death: 2 people, 11.76%
  8. Road Traffic Accident: 1 person, 5.88%
  9. Joint Pain: 1 person, 5.88%
  10. High Blood Cholesterol: 1 person, 5.88%

What are the existing conditions these people have? *

  1. Stress And Anxiety: 9 people, 52.94%
  2. Nausea (feeling of having an urge to vomit): 9 people, 52.94%
  3. Crohn's Disease (a condition that causes inflammation of the gastrointestinal tract): 4 people, 23.53%
  4. Osteoporosis (bones weak and more likely to break): 1 person, 5.88%
  5. Hypersensitivity: 1 person, 5.88%
  6. Cardiac Disorder: 1 person, 5.88%
  7. Atrial Fibrillation/flutter (atrial fibrillation and flutter are abnormal heart rhythms in which the atria, or upper chambers of the heart, are out of sync with the ventricles): 1 person, 5.88%
  8. Asthma: 1 person, 5.88%

* Approximation only. Some reports may have incomplete information.

Do you take Tysabri and have T-cell lymphoma?

- Check whether T-cell lymphoma is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, long term effects of, and alternative drugs to Tysabri:

T-cell lymphoma treatments and more:

How severe was T-cell lymphoma and when was it recovered:

Expand to all the drugs that have ingredients of natalizumab:

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Tysabri:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with T-cell lymphoma:

Browse all the conditions that are associated with T-cell lymphoma:


How the study uses the data?

The study uses data from the FDA. It is based on natalizumab (the active ingredients of Tysabri) and Tysabri (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: